ZUMA-23: A first-line CAR-T trial in LBCL, presented at ASCO 2023 The Phase 3 ZUMA-23 trial will evaluate the efficacy of axi-cel as a first-line treatment for LBCL patients. This study is currently enrolling at Australian sites.
